Executive Summary
Nighthawk Biosciences, parent of Elusys Therapeutics, captured a $124.5M non-competitive HHS contract for Anthim biodefense drug, fully obligating base plus all options through 2028-12-31 and signaling strong multi-year revenue visibility. Low outlay progress at $17.7M (14%) flags potential delays in cash flow recognition. Investors should prioritize this as a concentrated bullish exposure to HHS preparedness spending amid biodefense priorities.
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from January 21, 2026.
Investment Signals(1)
- $124.5M HHS Anthim contract fully obligated(HIGH)▲
Non-competitive award provides firm fixed-price revenue stream from 2024-2028, with $17.7M outlayed to date in pharmaceutical manufacturing for biodefense.
Risk Flags(1)
- Execution[HIGH RISK]▼
Firm fixed-price structure exposes contractor to cost overruns over 4.67-year period; only 14% ($17.7M of $124.5M) outlayed signals delayed revenue recognition.
Opportunities(1)
- ◆
Full obligation includes all options; non-competitive HHS ASPR award in preparedness space positions for follow-on contracts.
Sector Themes(1)
- ◆
Single large non-competitive contract highlights sustained ASPR/ORM-SNS funding for biological countermeasures like Anthim (NAICS 325412, PSC 6505).
Watch List(1)
- 👁
{"entity"=>"Nighthawk Biosciences, Inc.", "reason"=>"Dominates period with $124.5M HHS exposure; low outlay progress could impact near-term financials.", "trigger"=>"Outlay acceleration >20% QoQ or follow-on award announcements"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC